GERN Geron Corp.

Geron to Present at Needham Virtual Healthcare Conference

Geron to Present at Needham Virtual Healthcare Conference

MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 19th Annual Needham Virtual Healthcare Conference at 10:00 a.m. ET on Wednesday, April 15, 2020.

A live audio webcast of the presentation will be available on Geron’s website, . If you are unable to listen to the live presentation, an archived webcast will be available on the Company’s website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit .

CONTACT:

Suzanne Messere

Investor and Media Relations

 

 

CG Capital

877-889-1972

EN
08/04/2020

Underlying

GERNGeron Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Geron Corp.

 PRESS RELEASE
Free
GERN GERON CORP.

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule ...

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stock options to purchase an aggregate of 320,000 shares of common stock to one newly hired employee as an inducement material to such employee’s acceptance of employment with Geron. The stock options have an exercise price of $1.34 per share, which is equal to the closing price of Geron’s common stock on the grant ...

December 18, 2025 1 EN
 PRESS RELEASE
Free
GERN GERON CORP.

Geron Corporation Announces Strategic Restructuring Plan to Position t...

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced a strategic restructuring plan intended to position the Company for long-term value creation for patients and shareholder...

December 11, 2025 1 EN
Wedbush Research
  • Wedbush Research
TSLA TESLA INC
SRPT SAREPTA THERAPEUTICS INC.
KURA KURA ONCOLOGY INC.
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
AMZN AMAZON.COM INC.
ARVN ARVINAS HOLDING
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
DASH DOORDASH
IMNM IMMUNOME
SANA SANA BIOTECHNOLOGY
CGEM CULLINAN ONCOLOGY INC
TCRX TSCAN THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
PRME PRIME MEDICINE INC
CART MAPLEBEAR INC.
12/09/25 December 9, 2025 1 EN
David Nierengarten ... (+6)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
ARVN ARVINAS HOLDING
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
IMNM IMMUNOME
SANA SANA BIOTECHNOLOGY
TCRX TSCAN THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
PRME PRIME MEDICINE INC
12/09/25 December 9, 2025 1 EN
 PRESS RELEASE
Free
GERN GERON CORP.

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relat...

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in lower-risk MDS Long-term follow-up analysis from IMerge supports favorable survival trends and durable clinical benefit in LR-MDS Additional analyses in myelofibrosis an...

December 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch